D. Behan

发表

Ligand requirements of the human corticotropin-releasing factor-binding protein.

S. Lahrichi, W. Vale, J. Rivier, 1995, Endocrinology.

Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.

S. H. Kim, Michael E. Morgan, Robert M. Jones, 2015, Bioorganic & medicinal chemistry letters.

Corticotrophin-releasing factor receptors: from molecular biology to drug design.

T. Lovenberg, E. D. De Souza, D. Grigoriadis, 1996, Trends in pharmacological sciences.

Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia

R. Luthringer, C. Anderson, Michael E. Morgan, 2010, Journal of Pharmacology and Experimental Therapeutics.

Langerhans cells release prostaglandin D2 in response to nicotinic acid.

D. Connolly, Y. Hakak, I. Gaidarov, 2006, The Journal of investigative dermatology.

Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors*

D. Connolly, S. Wright, Douglas P. Boatman, 2007, Journal of Biological Chemistry.

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.

D. Connolly, S. Tamura, C. Sage, 2008, Journal of medicinal chemistry.

Circulating corticotropin-releasing factor in pregnancy.

C. Wolfe, E. Linton, D. Behan, 1990, Advances in experimental medicine and biology.

A SPECIFIC CARRIER SUBSTANCE FOR HUMAN CORTICOTROPHIN RELEASING FACTOR IN LATE GESTATIONAL MATERNAL PLASMA WHICH COULD MASK THE ACTH‐RELEASING ACTIVITY

C. Wolfe, E. Linton, D. Behan, 1988, Clinical endocrinology.

Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues.

V. Cameron, P. Sawchenko, F. Petraglia, 1993, The Journal of clinical endocrinology and metabolism.

Corticotropin Releasing Factor (CRF) Binding Protein: A Novel Regulator of CRF and Related Peptides

W. Vale, D. Behan, P. Lowry, 1995, Frontiers in Neuroendocrinology.

Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.

I. Gaidarov, Michael E. Morgan, K. Whelan, 2015, Bioorganic & medicinal chemistry letters.

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

D. Rader, D. Connolly, Jiajun Liu, 2012, Science Translational Medicine.

Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke.

N. Ling, E. D. De Souza, Xin-jun Liu, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat

C. Sage, Michael E. Morgan, K. Whelan, 2014, Psychopharmacology.

Modulation of sphingosine-1-phosphate in inflammatory bowel disease.

L. Peyrin-Biroulet, D. Behan, C. Lassen, 2017, Autoimmunity reviews.

Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy.

W. Vale, C. Wolfe, A. Perkins, 1993, The Journal of clinical endocrinology and metabolism.

Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.

John W. Adams, A. Blackburn, I. Gaidarov, 2017, Journal of medicinal chemistry.

Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal.

N. Ling, S. Heinrichs, P. Sawchenko, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor.

G. Milligan, F. Zeng, D. Behan, 2002, Molecular pharmacology.

The role of the GPR91 ligand succinate in hematopoiesis

D. Connolly, Y. Hakak, C. Liaw, 2009, Journal of leukocyte biology.

Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.

T. Lovenberg, S. Heinrichs, E. D. De Souza, 1996, Molecular psychiatry.

Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex.

A. Grossman, W. Vale, P. Saphier, 1994, The Journal of clinical endocrinology and metabolism.

Section Review: Central & Peripheral Nervous Systems: Corticotropin releasing factor and Alzheimer's disease: recent developments with implications for more effective therapies

S. Heinrichs, D. Behan, E. D. Souza, 1996 .

Measurement of corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in human plasma by two-site enzyme-linked immunoabsorbant assay.

N. Ling, E. D. De Souza, R. Goland, 1996, The Journal of clinical endocrinology and metabolism.

Constitutively activated G protein-coupled receptors: a novel approach to CNS drug discovery.

F. Menzaghi, D. Behan, D. Chalmers, 2002, Current drug targets. CNS and neurological disorders.

Corticotropin releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic cells

D. Behan, D. Chalmers, D. Maciejewski, 1995, Brain Research.

APD791, 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a Novel 5-Hydroxytryptamine 2A Receptor Antagonist: Pharmacological Profile, Pharmacokinetics, Platelet Activity and Vascular Biology

John W. Adams, D. Connolly, Michael E. Morgan, 2009, Journal of Pharmacology and Experimental Therapeutics.

Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist.

John W. Adams, D. Connolly, P. Dosa, 2008, European journal of pharmacology.

Peripheral CRF-R1/CRF-R2 antagonist, astressin C, induces a long-lasting blockade of acute stress-related visceral pain in male and female rats

Y. Taché, M. Larauche, D. Behan, 2022, Peptides.

Chapter 3. Heterogeneity of Corticotropin Releasing Factor Receptors: Multiple Targets for the Treatment of CNS and Inflammatory Disorders

T. Lovenberg, D. Grigoriadis, C. Liaw, 1995 .

(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.

A. Blackburn, I. Gaidarov, S. H. Kim, 2014, ACS medicinal chemistry letters.

Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins

W. Fischer, W. Vale, E. Linton, 1991, Nature.

Diet‐Induced Models of Obesity (DIO) in Rodents

K. Whelan, A. Grottick, D. Behan, 2012, Current protocols in neuroscience.

Corticotropin-releasing hormone (CRH)-binding protein: reduction in the adrenocorticotropin-releasing activity of placental but not hypothalamic CRH.

E. Linton, P. Saphier, D. Behan, 1990, The Journal of clinical endocrinology and metabolism.

Ligand specific up-regulation of a Renilla reniformis luciferase-tagged, structurally unstable muscarinic M3 chimeric G protein-coupled receptor.

G. Milligan, F. Zeng, D. Behan, 2003, Molecular pharmacology.

The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF.

P. Sawchenko, W. Vale, E. Linton, 1992, Proceedings of the National Academy of Sciences of the United States of America.

G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.

C. Bjenning, W. Thomsen, D. Behan, 2004, Current opinion in investigational drugs.

Regulation of corticotropin-releasing factor-binding protein expression in cultured rat astrocytes.

E. D. De Souza, P. Crowe, D. Behan, 1996, The Journal of pharmacology and experimental therapeutics.

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

Brian M. Smith, F. Menzaghi, Michael Martin, 2008, Journal of Pharmacology and Experimental Therapeutics.

Generation and Analysis of Constitutively Active and Physically Destabilized Mutants of the Human (cid:1) 1 -Adrenoceptor

G. Milligan, F. Zeng, D. Behan, 2002 .

Myocardial expression, signaling, and function of GPR22: a protective role for an orphan G protein-coupled receptor.

John Ross, John W. Adams, J. Ross, 2008, American journal of physiology. Heart and circulatory physiology.

2.20 – G Protein-Coupled Receptors

W. Thomsen, D. Behan, 2007 .

N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.

Robert M. Jones, D. Unett, D. Behan, 2010, Molecular endocrinology.

The use of constitutively active GPCRs in drug discovery and functional genomics

D. Behan, D. Chalmers, Derek T. Chalmers, 2002, Nature Reviews Drug Discovery.

Neurotransmission- and cellular stress-related gene expression associated with prepulse inhibition in mice.

Y. Hakak, J. McDonald, A. Grottick, 2005, Brain research. Molecular brain research.

Global analysis of G‐protein‐coupled receptor signaling in human tissues

Y. Hakak, D. Behan, D. Chalmers, 2003, FEBS letters.

Characterization of a sheep brain corticotropin releasing factor binding protein

W. Fischer, W. Vale, S. Sutton, 1996, Brain Research.

Urocortin interaction with corticotropin-releasing factor (CRF) binding protein (CRF-BP) : a novel mechanism for elevating ‘free’ CRF levels in human brain

D. Behan, O. Khongsaly, N. Ling, 1996, Brain Research.

Isolation of the human plasma corticotrophin-releasing factor-binding protein.

E. Linton, D. Behan, P. Lowry, 1989, The Journal of endocrinology.

Corticotropin‐Releasing Factor (CRF), CRF‐Binding Protein (CRF‐BP), and CRF/CRF‐BP Complex in Alzheimer's Disease and Control Postmortem Human Brain

C. Nemeroff, M. Owens, E. D. De Souza, 1997, Journal of neurochemistry.

Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease

N. Ling, S. Heinrichs, C. Kawas, 1995, Nature.

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.

Robert M. Jones, D. Behan, J. Leonard, 2008, Endocrinology.

Modulatory Actions of Corticotropin‐releasing Factor–binding Protein a

P. Sawchenko, W. Vale, D. Behan, 1996, Annals of the New York Academy of Sciences.

Cloning and structure of the human corticotrophin releasing factor-binding protein gene (CRHBP)

K. Lewis, N. Copeland, N. Jenkins, 1993, Genomics.

A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.

Didier Bagnol, Robert M. Jones, D. Unett, 2007, Endocrinology.

Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.

A. Blackburn, David Mills, I. Gaidarov, 2014, ACS medicinal chemistry letters.

Erratum: Cloning and structure of the human corticotrophin releasing factor-binding protein gene (CRHBP) (Genomics (1993) 16 (63-68))

K. Lewis, N. Copeland, N. Jenkins, 1994 .

Enhancement of Performance in Multiple Learning Tasks by Corticotropin-Releasing Factor-Binding Protein Ligand Inhibitors

S. Heinrichs, G. Schulteis, D. Behan, 1997, Peptides.

Circulating human corticotropin-releasing factor-binding protein levels following cortisol infusions.

J. Welge, S. Lupien, J. Kasckow, 2001, Life Science.

Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat

C. Sage, Michael E. Morgan, K. Whelan, 2014, Psychopharmacology.

Nature of ligand affinity and dimerization of corticotrophin-releasing factor-binding protein may be detected by circular dichroism.

W. Vale, J. Rivier, S. Sutton, 1996, Journal of molecular endocrinology.

APD811, a Novel and Highly Selective Non-prostanoid IP Receptor Agonist in Smooth Muscle Cells From Patients With Pulmonary Hypertension

John W. Adams, D. Behan, Lei Shen, 2016 .

Corticotropin-releasing factor binding protein dimerizes after association with ligand.

W. Vale, J. Gibbins, D. Behan, 1994, Endocrinology.

Assignment of disulfide bonds in corticotropin-releasing factor-binding protein.

W. Fischer, W. Vale, D. Behan, 1994, The Journal of biological chemistry.